Predictors of Health-Related QOL in Adults With CLL or Small Lymphocytic Lymphoma

Launched by H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE · Jun 20, 2025

Keywords

ClinConnect Summary

This clinical trial is studying how adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) feel over time while receiving treatment. The researchers want to learn more about changes in quality of life, tiredness (fatigue), and other symptoms during the first two years of treatment. They will compare two different treatment approaches to better understand what patients might expect, which can help doctors and future patients make informed decisions.

Adults aged 65 to 74 who have recently been diagnosed with CLL and are about to start specific treatments (either a BTKi drug with or without another antibody medicine, or a BCL2 inhibitor combined with Obinutuzumab) may be eligible to join. Participants need to be able to read and speak English or Spanish at about an 8th-grade level. People with serious memory problems, brain injuries, or cancer that has spread to the brain won’t be able to take part. If you join, you can expect to be followed for two years to track how you’re feeling and how your symptoms change with treatment. This study is still recruiting participants, so if you or a loved one fit these criteria, you might want to ask your doctor about this opportunity.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • All patients with pathology-confirmed diagnoses of CLL who are within seven days of starting treatment with a BTKi +/- an anti-CD 20 monoclonal antibody or BCL2i with Obinutuzumab treatment will be included.
• • Subjects must be able to read and speak English or Spanish at the 8th grade level.
• Exclusion Criteria:
• • Patients with dementia, traumatic brain injury, or individuals with central nervous system involvement of their leukemia will be excluded from study participation.